These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 24096029

  • 1. A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice.
    Li W, Murthy AK, Lanka GK, Chetty SL, Yu JJ, Chambers JP, Zhong G, Forsthuber TG, Guentzel MN, Arulanandam BP.
    Vaccine; 2013 Nov 19; 31(48):5722-8. PubMed ID: 24096029
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The role of an enzymatically inactive CPAF mutant vaccination in Chlamydia muridarum genital tract infection.
    Chen H, Peng B, Yang C, Xie L, Zhong S, Sun Z, Li Z, Wang C, Liu X, Tang X, Zhong G, Lu C.
    Microb Pathog; 2021 Nov 19; 160():105137. PubMed ID: 34390765
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge.
    Chaganty BK, Murthy AK, Evani SJ, Li W, Guentzel MN, Chambers JP, Zhong G, Arulanandam BP.
    Vaccine; 2010 Mar 08; 28(11):2323-9. PubMed ID: 20056182
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Outer membrane proteins preferentially load MHC class II peptides: implications for a Chlamydia trachomatis T cell vaccine.
    Karunakaran KP, Yu H, Jiang X, Chan Q, Moon KM, Foster LJ, Brunham RC.
    Vaccine; 2015 Apr 27; 33(18):2159-66. PubMed ID: 25738816
    [Abstract] [Full Text] [Related]

  • 15. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells.
    Yu H, Jiang X, Shen C, Karunakaran KP, Jiang J, Rosin NL, Brunham RC.
    Infect Immun; 2010 May 27; 78(5):2272-82. PubMed ID: 20231405
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model.
    Hansen J, Jensen KT, Follmann F, Agger EM, Theisen M, Andersen P.
    J Infect Dis; 2008 Sep 01; 198(5):758-67. PubMed ID: 18652549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.